Objective: The Society for Vascular Surgery (SVS) Wound, Ischemia and foot Infection (WIfI) classification system was proposed to predict 1-year amputation risk and potential benefit from revascularization. Our goal was to evaluate the predictive ability of this scale in a real-world selection of patients undergoing a first-time lower extremity revascularization for chronic limb-threatening ischemia (CLTI).
With the increasing global prevalence of diabetes and peripheral artery disease, use of the term chronic limb ischemia (CLI) is being applied to a wider spectrum of patients than was initially anticipated.
1,2 The current existing CLI classification systems fail to adequately categorize the extent of tissue loss and/or the degree of infection, and attempts to compare outcomes of different therapies have been deterred by the inconsistencies in the definition and the heterogeneity of clinical presentation. Importantly, controversies over revascularization approaches (ie, open bypass vs endovascular therapy) cannot be resolved without more precise stratification of the patients being treated. [3] [4] [5] [6] [7] [8] [9] Furthermore, given the constraints of in-place classification systems, such as the Rutherford class, and the currently fluctuating The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
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Copyright baseline risk of amputation compared with the pre-endovascular era, there is a pressing need for a better method to define risk in this population. 10 Ultimately, limitations from the Rutherford system make contemporary comparisons to historical numbers difficult and inaccurate.
To address this need for a more applicable classification arrangement that encompasses both the changing patient demographics of CLI as well as the expanded use of revascularization interventions, the Society for Vascular Surgery (SVS) Lower Extremity Guidelines Committee recently created the Lower Extremity Threatened Limb (Wound, Ischemia, foot Infection [WIfI]) Classification System. 11 The SVS WIfI classification system was developed by merging the existing CLI and diabetic foot ulcer classification systems and stratifies risk based on three major categories: wound, ischemia, and foot infection. 10, [12] [13] [14] [15] [16] Although there have been several recent comprehensive evaluations of the SVS WIfI classification system, [17] [18] [19] none have assessed its effect on first-time lower extremity revascularizations or its potential distinction between revascularization types. In this retrospective cohort study, we sought to evaluate the predictive ability of the SVS WIfI classification system, as well as our novel WIfI composite and WIfI mean scoring systems, after first-time lower extremity revascularizations for CLTI. Further, in hopes to confront the limitations and imprecise standard terminology of critical or chronic limb ischemia, this study hopes to invoke the removal of these terms when referring to this subset of patients and to replace them with "chronic limb-threatening ischemia" (CLTI).
METHODS
We performed a retrospective record review of all Beth Israel Deaconess Medical Center patients undergoing a first-time lower extremity revascularization for CLTI between 2005 and 2014. The Beth Israel Deaconess Medical Center Institutional Review Board approved this study and waived the need for patient consent due to the retrospective design.
Patients were identified using Current Procedural Terminology (American Medical Association, Chicago, Ill) codes for open bypass and endovascular revascularizations. The analysis excluded patients with any prior lower extremity revascularization(s), patients without CLTI symptoms, patients undergoing endovascular procedures that were aborted because of a failure to cross the lesion, patients undergoing a diagnostic angiogram, and patients missing an initial grade in any of the three individual WIfI components. The typical follow-up interval was every 3 to 4 months for 2 years and every 6 months thereafter with arterial duplex ultrasound imaging, ankle-brachial indices, and forefoot or toe pressure recordings, or both.
A retrospective study was performed to assess the predictive ability of the WIfI classification system. The SVS WIfI classification system was developed in 2013 and provides an objective classification for wound healing and limb amputation based on three independent risk factorsdwound extent, degree of ischemia, and extent of foot infectiondthat are combined to create a WIfI clinical stage that predicts the risk of limb amputation at 1 year and, in a separate analysis, the likelihood that the patient would benefit from limb revascularization. 11 All three factors are individually graded on a scale of 0 (least severe) to 3 (most severe In addition, for statistical purposes, a further subclassification was created within the WIfI composite scores, where limbs were stratified into low-risk (composite scores 1-3), moderate-risk (4-6), and high-risk groups (7) (8) (9) . Finally, as will be discussed further in the Results and Discussion, the similarity between outcomes in clinical stage 2 and 3 limbs prompted an additional substratification in which these two stages were consolidated, generating a three-leveled clinical staging system referred to as the WIfI simplified stages (1-3).
Indications for intervention included tissue loss (eg, ulcer or gangrene) or rest pain. Patient limbs presenting with more than one indication were assigned as having only the most severe symptom, with gangrene being the most severe, followed by ulcer, and lastly, rest pain. All analyses were performed on a per-limb basis. Pearson c 2 and Fisher exact tests were used for comparisons of categoric variables. Means of continuous variables were compared using the Student t test, assuming equal variances where appropriate. Primary outcomes included major amputation; reintervention, major amputation, or stenosis (3.5Â step-up by duplex; RAS) events; and death. Bivariate and multivariable predictors of these outcomes were identified using the log-rank test and Cox proportional hazards regression modeling. The unit of analysis for the study's primary outcomes was at the limb level for limb-based outcomes (ie, major amputation and RAS events) and at the patient level for patient-level outcomes (ie, mortality), where a patient's first procedure was used as the point of reference and only counted once. The statistical analyses were performed using STATA 12 software (StataCorp LP, College Station, Tex).
RESULTS
Between 2005 and 2014, 2869 limbs underwent a lower extremity revascularization, of which 1336 fit our criteria of a first-time revascularization for CLTI. Of these 1336 limbs, 992 limbs in 903 patients were classified in all three WIfI components on a scale from 0 to 3, 524 bypass-first limbs and 468 endovascular-first limbs (24% rest pain and 74% tissue loss). Mean patient follow-up Table I . Consensus expert estimates of 1-year amputation risk based on the collaboration of Wound characteristic, Ischemia, and foot Infection (WIfI) grades 11 Table II . Patients in this analysis were more often male (59%), and the average age was w71 years. Common comorbidities included hypertension (85%), diabetes (73%), coronary artery disease (49%), congestive heart failure (30%), and chronic renal failure resulting in dialysis dependence (17%). A history of smoking, which includes current use and consistent use at any point throughout a patient's life, was documented in 61% of the patients. The c 2 analysis showed several demographic differences between the bypass-only and endovascular-only cohorts, including age (70.4 vs 72.2 years; P ¼ .03), hypertension (82% vs 88%; P ¼ .03), dialysis dependence (14% vs 21%; P < .01), chronic obstructive pulmonary disease (15% vs 10%; P ¼ .03), and a history of smoking (70% vs 54%; P < .001).
1-Year amputation
After converting the initial wound, ischemia, and foot infection data of the study population into individual WIfI components and, further, into a specific WIfI clinical stage (1-4), we were able to parallel our observed 1-year limb amputation rates with the Mills et al WIfI clinical stage rubric (Table III) . As summarized in Tables III and IV, rates of limb salvage and survival decrease as clinical stage increases. Importantly, Table IV also demonstrates the more uniform and continued decrease in limb salvage, freedom from RAS events, and survival as the WIfI simplified stages increase. Further, the WIfI composite substratification shows a similar pattern (Table V) , where an increase in risk grouping coincides with an increasing risk of major amputation, RAS events, and mortality among all patients (hazard ratios [HRs], 3.0, 1.3, and 1.2, respectively) and bypass only patients (HRs, 2.5, 1.4, and 1.3, respectively). All reported in-text HR values are statistically significant (ie, P < .05), and the confidence intervals can be viewed in Table VI . Additional Cox regression models showed that among all patients, a one-unit increase in clinical stage increases the risk of major amputation (2.4) and RAS events (1.2). Similarly, among all patients, a separate regression model showed that a one-unit increase in the WIfI composite score is also associated with an increase in the risk of major amputation (1.8), RAS events (1.2), and mortality (1.1). Finally, among all patients, regression models showed that a oneunit increase in the WIfI mean score is associated with the greatest risk of major amputation (5.3), RAS events (1.7), and mortality (1.4). The novel WIfI composite and WIfI mean scores were the only consistent predictors of mortality among the three cohorts, whereas the WIfI clinical staging system was not associated with mortality in any of the three cohorts.
Multivariable analyses (Table VI) showed that major amputation was predicted by all WIfI scoring systems in each cohort (ie, all patients, bypass only, and endovascular only). In addition to predicting major amputation and RAS events among all patients, increasing one clinical stage also proved to increase the risk of major amputation (1.8) and RAS events (1.3) in the bypass-only cohort, as well as major amputation in the endovascular-only cohort (3.5). Further, the WIfI simplified stages proved predictive of major amputation, RAS events, and mortality among all patients (4.5, 1.5, 1.4, respectively) and bypass-only patients (4.1, 1.7, 1.5, respectively), as well as major amputation (4.9) and RAS events (1.3) in the endovascular-only patients. Overall, WIfI clinical stages were able to significantly predict five of the nine primary end points (ie, major amputation, RAS events, and mortality in all three cohorts), and the Composite (2-9) CI, Confidence interval; HR, hazard ratio; RAS, reintervention, amputation, or stenosis. Data in bold are statistically significant (P < .05). a Adjusted for age, gender, smoking, renal disease, diabetes, and congestive heart failure.
WIfI simplified stages were able to significantly predict eight of nine primary end points. Importantly, separate multivariable analyses proved that an increase in our novel WIfI mean score or WIfI composite score proved the most consistently predicative in regards to our primary outcomes, with both scoring systems predicting all nine primary outcomes throughout each cohort. Specifically, in addition to predicting major amputation, RAS events, and mortality among all patients, the WIfI composite score also proved predictive for all three end points in the bypass-only cohort (1.6, 1.3, and 1.1, respectively) and in the endovascular-only cohort (1.9, 1.1, and 1.1, respectively) . Ultimately, the WIfI mean score proved most predictive of all of the WIfI scoring systems. In addition to predicting major amputation, RAS events, and mortality among all patients, the novel WIfI mean score was also able to significantly predict all three primary outcomes in the bypass-only cohort (4.1, 1.9, and 1.5, respectively) and in the endovascular-only cohort (6.6, 1.4, and 1.4, respectively).
Increases in the individual WIfI components (wound, ischemia, and foot infection) also proved valuable in predicting long-term outcomes. Most notably, the individual wound component significantly predicted major amputation (1.7) and mortality (1.1) within the entire cohort, major amputation (1.5), RAS events (1.2), and mortality (1.0) within the bypass-only cohort, and major amputation (1.8) within the endovascular-only cohort. Further, these data reveal the ability of the individual ischemia component to significantly predict major amputation and RAS events in both the entire cohort (2.8 and 1.5, respectively) and the endovascularonly cohort (3.6 and 1.8, respectively). Finally, the individual WIfI infection component predicted major amputation within each of the three cohorts (entire cohort: 1.8; bypass only: 1.6; endovascular only: 1.9).
Kaplan-Meier survival estimates and log-rank analysis illustrate the significant difference between freedom from major amputation between clinical stage 4 patients and clinical stage 2 and 3 patients (69% vs 92% and 93% at 3 years, respectively; P < .001 [clinical stage 1 limbs were included in Figs 1 and 2 but removed from analysis due to low sample size]); however, as Fig 1 indicates , there appears to be substantial heterogeneity within the clinical stage 4 stratification. Furthermore, as Table III and Fig 2 illustrate, although log-rank analysis suggests a significant difference in freedom from RAS events within the clinical stage stratification (P < .001), clinical stage 2 patients were noted to have lower rates of freedom from RAS events than clinical stage 3 patients (57% vs 61% at 1 year and 42% vs 49% at 3 years). Importantly, Kaplan-Meier survival estimates and log-rank analysis in the substratification of the WIfI composite score appear to identify this heterogeneity in the clinical staging by showing a much more progressive significant difference in limb salvage rates and freedom from RAS events at 3 years between patients with a low-risk (composite 1-3), moderate-risk (4-6), and high-risk (7-9) WIfI composite score (limb salvage: 92% vs 83% vs 46%, respectively, P < .001, Fig 3; freedom from RAS events: 45% vs 39% vs 14%, respectively, P < .001, Fig 4) . In order to eliminate any potential concern regarding lack of independence of observations within this cohort, a separate sensitivity analysis limited to the first limb in patients who had bilateral limb interventions was performed and illustrated no appreciable changes in any of our findings. Further, as a means to account for any potential effect that the changing of practice patterns may have had throughout our study's time line, we performed an additional sensitivity analysis restricted to the study's early (2005) (2006) (2007) (2008) (2009) ) and late (2010-2014) years. Ultimately, restriction of the analysis to these years did not yield any substantial differences in any of our primary outcomes of interest.
DISCUSSION
Our data illustrate that for those undergoing a first-time revascularization for CLTI, limbs categorized as having higher grades in any of the WIfI scoring systems have a significantly increased risk of undergoing a future major amputation, regardless of the initial revascularization procedure. Most saliently, among the three primary outcomes (major amputations, RAS events, and mortality) and within each separate cohort (all patients, bypass only, and endovascular only), the novel WIfI composite and WIfI mean scores proved most consistent, predicting all outcomes in each cohort. Ultimately, although prediction of mortality and RAS events were not the primary outcomes of the original Mills et al 11 Although this new stratification should be further evaluated, we do not believe that the cohort within this study is sufficient to make any substantial claims. Regardless of the specific scoring methodology, however, we believe that this studydas well as our previous WIfI studydadds significant support for the value and utility of the WIfI classification system and its related components. 20 In particular, prospectively, the WIfI classification system can be used to stratify a patient's risk of amputation at presentation and during treatment, which can help guide the clinician on how aggressive to be for limb salvage. We found the WIfI composite and WIfI mean scores were most useful in consistently predicting outcomesdincluding risk for amputationdwhere their easy-to-conceptualize nature allows for quick incorporation into clinical practice. Retrospectively, the WIfI system can be useful for comparative effectiveness analysis, because it is successful across all treatment modalities in predicting risk of amputation, RAS events, and mortality.
It is important to note that none of the limbs within our cohort were classified as having an ischemia grade of 0. Although the expert consensus on the 1-year amputation risk proposes the potential for some of these limbs to be high risk, our cohorts were constructed exclusively from those undergoing revascularization. Because of this identification methodology, we were unable to properly validate the risk of amputation in this specific cohort of patients. Similarly, we were unable to address the Mills et al 11 staging of the proposed benefit from revascularization, because we had no limbs that did not undergo a revascularization.
This study has some additional limitations. The small number of limbs within WIfI clinical stage 1 may provide statistical deficiencies. Further, as a retrospective study, the potential for selection and information bias exists. Because our data represent the experience of one group of surgeons at a single institution, our results are subject to the influence of specific referral patterns, surgeon experience, and patient selection preferences. Although our study investigates the largest cohort in support of the WIfI classification system, because this series only addresses patients who underwent revascularization, prospective and multicenter studies comprising all-comers with limb threat are justified to fully validate this newly proposed system.
CONCLUSIONS
We believe that these data have proven the particular significance of the WIfI composite and mean scores as a supplement to, or replacement of, the WIfI clinical stages. In addition to our data showing that both systems are more consistently predictive of our outcomes in question, we believe that these scoring systems are easier to conceptualize, give equal weight to each of the WIfI variables, and provide clinicians easier comparisons in outcomes between patients. In addition, given that both novel systems give equal weight to the three individual WIfI components, the WIfI mean score may prove particularly useful in predicting outcomes in patients who may be missing necessary information to provide a grade in any of the individual components.
Furthermore, as our data illustrate, these novel scores address the apparent heterogeneity and inconsistencies in the clinical stage stratification, as illustrated by the nonlinear trends within our survival estimates. Although further studies of the WIfI composite and mean scores are warranted, we believe that these novel stratifications more adequately and comprehensively categorize the extent of tissue loss or the degree of infection that the WIfI classification system hopes to address. 
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